Implications of circulating neurofilaments for spinal muscular atrophy treatment early in life: A case series-Reference-Cited by-同舟云学术

Implications of circulating neurofilaments for spinal muscular atrophy treatment early in life: A case series

Published:2021-12 Issue: Volume:23 Page:524-538
ISSN:2329-0501
Container-title:Molecular Therapy - Methods & Clinical Development
language:en
Short-container-title:Molecular Therapy - Methods & Clinical Development

Author:

Alves Christiano R.R.^ORCID,Petrillo Marco,Spellman Rebecca,Garner Reid,Zhang Ren^ORCID,Kiefer Michael^ORCID,Simeone Sarah^ORCID,Sohn Jihee,Eichelberger Eric J.^ORCID,Rodrigues Emma,Arruda Elizabeth A.,Townsend Elise L.^ORCID,Farwell Wildon^ORCID,Swoboda Kathryn J.^ORCID

Funder

NIH

Publisher

Elsevier BV

Subject

Genetics,Molecular Biology,Molecular Medicine

Reference34 articles.

1. Advances in therapy for spinal muscular atrophy: promises and challenges;Groen;Nat. Rev. Neurol.,2018

2. Nusinersen versus sham control in infantile-onset spinal muscular atrophy;Finkel;N. Engl. J. Med.,2017

3. Nusinersen versus sham control in later-onset spinal muscular atrophy;Mercuri;N. Engl. J. Med.,2018

4. A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier;Sturm;Br. J. Clin. Pharmacol.,2019

5. Single-dose gene-replacement therapy for spinal muscular atrophy;Mendell;N. Engl. J. Med.,2017

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The limited role of serum neurofilament light chain in predicting pain severity of patients with diabetic polyneuropathy;Scientific Reports;2024-07-06

2. Insights into spinal muscular atrophy from molecular biomarkers;Neural Regeneration Research;2024-06-26

3. Apilimod dimesylate in C9orf72 amyotrophic lateral sclerosis: a randomized phase 2a clinical trial;Brain;2024-04-12

4. A Case of Spinal Muscular Atrophy Type 3a Showing Improvement in Neurofilament Light Chain of Cerebrospinal Fluid: Real-world Evidence;Journal of the Korean Neurological Association;2024-02-01

5. Challenges and opportunities in spinal muscular atrophy therapeutics;The Lancet Neurology;2024-02